Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes

Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes

Abstract Background Patients with type 2 diabetes (T2D) treated with glucagon-like peptide-1 receptor agonists may experience reductions in weight and blood pressure. The primary objective of the current study was to determine the weight-dependent and weight-independent effects of ~ 6 months treatme...

Full description

Bibliographic Details
Main Authors:	Keith C. Ferdinand, Julia Dunn, Claudia Nicolay, Flora Sam, Emily K. Blue, Hui Wang
Format:	Article
Language:	English
Published:	BMC 2023-03-01
Series:	Cardiovascular Diabetology
Subjects:	Blood pressure Diabetes Dulaglutide Glucagon-like peptide-1 Hypertension Weight
Online Access:	https://doi.org/10.1186/s12933-023-01775-x

Similar Items

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
by: Manige Konig, et al.
Published: (2021-09-01)

Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real‐world clinical practice: 36 month post‐marketing observational study
by: Rina Chin, et al.
Published: (2023-02-01)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
by: Marina V. Shestakova, et al.
Published: (2017-08-01)

Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies
by: Shuichi Suzuki, et al.
Published: (2017-06-01)

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
by: Lee J, et al.
Published: (2019-12-01)

Hypersensitivity to glucagon‐like peptide‐1 receptor agonists: A case of delayed urticaria‐like rash to dulaglutide and literature review
by: Leonardo Bianchi, et al.
Published: (2024-03-01)

An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis
by: Daisuke Ugamura, et al.
Published: (2022-06-01)

Effect of dulaglutide injection on weight beyond glycemic control: Real-world observational study
by: Adel G. Mohammed, et al.
Published: (2023-02-01)

The use of the GLP-1 analog - dulaglutide in the treatment of morbid obesity - case report
by: Agata Juda, et al.
Published: (2022-11-01)

Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus
by: Dandan Xie, et al.
Published: (2022-10-01)

Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway
by: Jinmi Lee, et al.
Published: (2022-02-01)

The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology
by: Sofía Echeverry-Guerrero, et al.
Published: (2024-11-01)

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
by: Michael A. Nauck, et al.
Published: (2021-04-01)

GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review
by: Laurence Aoun, et al.
Published: (2024-03-01)

Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?
by: Mahmoud M Mosli, et al.
Published: (2017-01-01)

Transformative weight loss with Dulaglutide: A case report of success in a challenging patient profile of an ex‐sumo wrestler
by: Sohail Bade, et al.
Published: (2024-09-01)

Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial
by: Antonino Tuttolomondo, et al.
Published: (2021-01-01)

Short-term monotherapy with Liraglutide for weight management: A case study
by: Feras Almarshad
Published: (2019-01-01)

Exacerbation of atrial fibrillation related to dulaglutide use
by: Jayden Lee, et al.
Published: (2021-05-01)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
by: Takahiro Iijima, et al.
Published: (2023-06-01)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
by: Thompson AM, et al.
Published: (2016-05-01)

Efficacy and safety of dulaglutide: a novel once-weekly glucagon-like peptide-1 analogue
by: A. S. Pogorelova, et al.
Published: (2018-03-01)

Glucagon-like Peptide-1 Receptor Agonists: Are They as Good as They Seem? A Systematic Review of Severe Adverse Effects
by: Pranjal Sharma, et al.
Published: (2024-08-01)

Mode of administration of dulaglutide: implications for treatment adherence
by: Amblee A
Published: (2016-06-01)

Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension
by: Nik Krajnc, et al.
Published: (2023-07-01)

Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients
by: Jhih-Wei Dai, et al.
Published: (2024-11-01)

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors
by: Jonas Ronn, et al.
Published: (2017-12-01)

Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study
by: Torre E, et al.
Published: (2020-04-01)

GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
by: Ziqi Zhang, et al.
Published: (2023-07-01)

Corrigendum: GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
by: Ziqi Zhang, et al.
Published: (2023-10-01)

Energy intake as a short‐term biomarker for weight loss in adults with obesity receiving liraglutide: A randomized trial
by: Aditi R. Saxena, et al.
Published: (2021-06-01)

Achieving the composite end‐point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once‐weekly dulaglutide in Chinese patients with type 2 diabetes: A post‐hoc analysis
by: Xinhua Xiao, et al.
Published: (2020-05-01)

Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
by: Kutoh Eiji, et al.
Published: (2019-07-01)

CORRELATION BETWEEN PRE AND POSTOPERATIVE LEVELS OF GLP-1/GLP-2 AND WEIGHT LOSS AFTER ROUX-EN-Y GASTRIC BYPASS: A PROSPECTIVE STUDY
by: Everton CAZZO, et al.
Published: (2016-12-01)

Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment
by: Chen S, et al.
Published: (2024-03-01)

Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trialResearch in context
by: Sophia Lengsfeld, et al.
Published: (2023-03-01)

Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review
by: Hwi Seung Kim, et al.
Published: (2021-11-01)

Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin
by: Hiroyuki Uchinuma, et al.
Published: (2020-05-01)

Dulaglutide‐combined basal plus correction insulin therapy contributes to ideal glycemic control in non‐critical hospitalized patients
by: Nobutoshi Fushimi, et al.
Published: (2020-01-01)

Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment [Letter]
by: Panjaitan NSD, et al.
Published: (2024-04-01)